Related Experiment Video

Updated: Aug 16, 2026

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
06:21

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

Sarcomas and pharmacogenetics

Paola Biason1, Giuseppe Toffoli

  • 1CRO, National Cancer Institute, Experimental and Clinical Pharmacology, Via Pedemontana Occidentale, 12 33081 Aviano, PN, Italy.

Pharmacogenomics
|September 7, 2005
PubMed

Insights

Pharmacogenetics significantly impacts chemotherapy response and toxicity in various sarcoma subtypes. Identifying predictive genetic markers is crucial for tailoring treatments for soft tissue sarcomas (STS) and bone sarcomas.

Area of Science:

  • Oncology
  • Pharmacogenetics
  • Cancer Chemotherapy

Background:

  • Sarcomas are diverse tumors necessitating tailored chemotherapy.
  • Chemotherapy response varies among sarcoma histologic subtypes.
  • Pharmacogenetics plays a key role in predicting patient response and toxicity to chemotherapy drugs.

Purpose of the Study:

  • To evaluate the impact of pharmacogenetics on chemotherapy efficacy in different sarcoma subtypes.
  • To identify potential genetic markers influencing treatment outcomes for soft tissue sarcomas (STS) and bone sarcomas.
  • To explore the role of genetic polymorphisms in drug metabolism, transport, and target proteins in sarcoma treatment.

Main Methods:

  • Review of existing literature on pharmacogenetic studies in sarcoma chemotherapy.
  • Analysis of polymorphisms in metabolizing enzymes (cytochrome P450, glutathione-S-transferase), transporter proteins (reduced folate carrier, P-glycoprotein), and target proteins (thymidylate synthase, methylenetetrahydrofolate reductase, dihydrofolate reductase, c-KIT).
  • Evaluation of pharmacogenetic implications for novel agents like imatinib in gastrointestinal tumors (GIST).

Main Results:

  • Genetic variations in enzymes, transporters, and targets can alter clinical outcomes, including response and toxicity.
  • Specific polymorphisms may influence the effectiveness of drugs like anthracyclines and alkylating agents.
  • The genetic basis for predicting phenotypic profiles in STS and bone sarcomas remains largely undetermined.

Conclusions:

  • Pharmacogenetic factors are critical for optimizing chemotherapy in sarcomas.
  • Further research is needed to identify reliable genetic markers for personalized sarcoma treatment.
  • Understanding genetic polymorphisms will advance the development of targeted therapies for sarcomas.

More Related Videos

The In ovo CAM-assay as a Xenograft Model for Sarcoma12:44

The In ovo CAM-assay as a Xenograft Model for Sarcoma

Published on: July 17, 2013

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...